Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Invicta DiagnosticNSE:INVICTA +3.88%21 Net Current Asset Value is ₹19.08 as of Mar. 2026, which is 100% below its 10-year median of 3.30. GuruFocus rates NSE:INVICTA with a GF Score™ of 21/100. The stock has 3 warning signs investors should review. Among 96 Medical Diagnostics & Research companies, Invicta Diagnostic ranks better than 57.29% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Invicta Diagnostic's net current asset value per share for the quarter that ended in Mar. 2026 was ₹19.08.
The historical rank and industry rank for Invicta Diagnostic's Net Current Asset Value or its related term are showing as below:
NSE:INVICTA'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.3 Med: 3.3 Max: 3.83
Current: 3.65
During the past 3 years, the highest Price-to-Net-Current-Asset-Value Ratio of Invicta Diagnostic was 3.83. The lowest was 3.30. And the median was 3.30.
NSE:INVICTA's Price-to-Net-Current-Asset-Value is ranked better than 57.29% of 96
companies
in the Medical Diagnostics & Research industry
Industry Median: 4.27
vs NSE:INVICTA: 3.65
Invicta Diagnostic (NSE:INVICTA) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Invicta Diagnostic Net Current Asset Value Related Terms
Invicta Diagnostic Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Invicta Diagnostic's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Invicta Diagnostic Net Current Asset Value Chart
Invicta Diagnostic Annual Data
Trend
Mar24
Mar25
Mar26
Net Current Asset Value
-1.87
-0.16
19.08
Invicta Diagnostic Semi-Annual Data
Mar24
Mar25
Sep25
Mar26
Net Current Asset Value
-1.87
-0.16
-0.13
19.08
NSE:INVICTA vs TMO, DHR, IDXX: Net Current Asset Value Comparison
For the Diagnostics & Research subindustry, Invicta Diagnostic's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Invicta Diagnostic Price-to-Net-Current-Asset-Value vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Invicta Diagnostic's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Invicta Diagnostic's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of ₹19.08 mean?
Invicta Diagnostic (NSE:INVICTA) has a Net Current Asset Value of ₹19.08 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Invicta Diagnostic and its competitors. This is 478% above median its historical median of 3.30. Over the past decade, Invicta Diagnostic's Net Current Asset Value has ranged from 3.30 to 3.83. According to the industry distribution chart, Invicta Diagnostic ranks #41 out of 96 companies in the Medical Diagnostics & Research industry, placing it in the top 42.7%.
Is Invicta Diagnostic's Net Current Asset Value too high?
Invicta Diagnostic's current Net Current Asset Value of ₹19.08 is 478% above median its 10-year median of 3.30. Over the past 10 years, this metric has ranged from a low of 3.30 to a high of 3.83. Based on the distribution chart, Invicta Diagnostic ranks #41 out of 96 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Invicta Diagnostic has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Invicta Diagnostic's Net Current Asset Value compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Invicta Diagnostic ranks #41 out of 96 companies for Net Current Asset Value. This puts Invicta Diagnostic in the upper half of its industry. The industry median Net Current Asset Value is 4.27. Historically, Invicta Diagnostic's own Net Current Asset Value has ranged from 3.30 to 3.83 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Medical Diagnostics & Research company?
The median Net Current Asset Value among Medical Diagnostics & Research companies is 4.27, based on 96 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Invicta Diagnostic and its competitors. For the Medical Diagnostics & Research industry, the median Net Current Asset Value is 4.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Invicta Diagnostic's current Net Current Asset Value is ₹19.08, which is 478% above median its own 10-year median of 3.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invicta Diagnostic stock overvalued right now?
Invicta Diagnostic (NSE:INVICTA) has a current Net Current Asset Value of ₹19.08. The current Net Current Asset Value is ₹19.08, which is 478% above median its 10-year median of 3.30. Invicta Diagnostic's overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Invicta Diagnostic (NSE:INVICTA), the current Net Current Asset Value is ₹19.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Invicta Diagnostic Ltd is engaged in the business of medical and diagnostic services and operates diagnostic centres providing medical testing and allied healthcare services in the Mumbai Metropolitan Region. The Company runs a diagnostic chain comprising seven diagnostic centres and one centralised laboratory across MMR in Maharashtra and operates under a hub and spoke model with a flagship hub in Thane, additional hub centres, spoke centres, and a centralised laboratory. Its service offerings include radiology and imaging, pathology and clinical laboratory tests, teleradiology, and services such as ultrasound, X Ray, CT scan, MRI scan, PET scan, and cardiac diagnostics, with patient convenience supported through home sample collection, house calls, and multiple report delivery options.
21GF Score
Get the complete analysis for NSE:INVICTA
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INVICTA has been successfully added to your 
